Literature DB >> 19312433

Use of Concentrated Human Serum gamma-Globulin in the Prevention and Attenuation of Measles.

C A Janeway.   

Abstract

Entities:  

Year:  1945        PMID： 19312433      PMCID： PMC1869384     

Source DB:  PubMed          Journal:  Bull N Y Acad Med        ISSN： 0028-7091


× No keyword cloud information.
  16 in total

1.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XX. THE DEVELOPMENT OF FIBRIN FOAM AS A HEMOSTATIC AGENT AND FOR USE IN CONJUNCTION WITH HUMAN THROMBIN.

Authors:  E A Bering
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

2.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XVI. FIBRIN CLOTS, FIBRIN FILMS, AND FIBRINOGEN PLASTICS.

Authors:  J D Ferry; P R Morrison
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

3.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XII. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PREVENTION AND ATTENUATION OF MEASLES.

Authors:  C W Ordman; C G Jennings; C A Janeway
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

4.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XVII. A NOTE ON THE ABSORPTION RATES OF FIBRIN FILMS IN TISSUE.

Authors:  P R Morrison; M Singer
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

5.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XIV. APPRAISAL OF ISOHEMAGGLUTININ ACTIVITY.

Authors:  E L Degowin
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

6.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. X. THE CONCENTRATIONS OF CERTAIN ANTIBODIES IN GLOBULIN FRACTIONS DERIVED FROM HUMAN BLOOD PLASMA.

Authors:  J F Enders
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

7.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XI. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PROPHYLAXIS AND TREATMENT OF MEASLES.

Authors:  J Stokes; E P Maris; S S Gellis
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

8.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXII. FIBRIN FILMS IN NEUROSURGERY, WITH SPECIAL REFERENCE TO THEIR USE IN THE REPAIR OF DURAL DEFECTS AND IN THE PREVENTION OF MENINGOCEREBRAL ADHESIONS.

Authors:  O T Bailey; F D Ingraham
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

9.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XV. THE PROTEINS CONCERNED IN THE BLOOD COAGULATION MECHANISM.

Authors:  J T Edsall; R M Ferry; S H Armstrong
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

10.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XVIII. FIBRINOGEN COAGULUM AS AN AID IN THE OPERATIVE REMOVAL OF RENAL CALCULI.

Authors:  J E Dees
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808
View more
  21 in total

1.  PASSIVE PROPHYLAXIS OF MEASLES.

Authors:  F T PERKINS
Journal:  Arch Gesamte Virusforsch       Date:  1965

2.  Chemical, physiological, and immunological properties and clinical uses of blood derivatives.

Authors:  E J COHN
Journal:  Experientia       Date:  1947-04-15

3.  Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.

Authors:  F Bouche; W Ammerlaan; F Berthet; S Houard; F Schneider; C P Muller
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

4.  An Urgent Need for "Common Cold Units" to Study COVID-19.

Authors:  Scott B Halstead
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

5.  COVID-19: The Need for Immunoprevention at Industrial Scale.

Authors:  Scott B Halstead
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

6.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.

Authors:  A P Durbin; M H Skiadopoulos; J M McAuliffe; J M Riggs; S R Surman; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 8.  Small Molecules and Antibodies for Zika Therapy.

Authors:  Xuping Xie; Jing Zou; Chao Shan; Pei-Yong Shi
Journal:  J Infect Dis       Date:  2017-12-16       Impact factor: 5.226

Review 9.  History of passive antibody administration for prevention and treatment of infectious diseases.

Authors:  Barney S Graham; Donna M Ambrosino
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

Review 10.  Wanted, dead or alive: new viral vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.